Intrauterine Device Market Size, Share, Growth, and Industry Analysis, By Type (Hormonal IUD, Copper IUD), By Application (Age 20-24, Age 25-34, Age 35-44), Regional Insights and Forecast to 2035

Intrauterine Device Market Overview

Global Intrauterine Device Market size is projected to reach USD 4720.08 Million by 2035, rising from USD 3377.58 Million in 2026 at a CAGR of 3.79%.

The Intrauterine Device Market is expanding due to increasing contraceptive awareness, rising family planning programs, and growing preference for longacting reversible contraception methods. More than 160 million women globally used modern contraceives during 2025, while intrauterine devices accounted for nearly 18% of longacting contraceptive adoption. Hormonal intrauterine devices represented 61% of total device usage, while copper intrauterine devices contributed 39%. Healthcare institutions in over 120 countries included intrauterine devices in public reproductive health programs during 2025. More than 78% of gynecologists in developed economies recommended intrauterine devices because of efficacy rates above 99% and replacement cycles extending from 3 years to 10 years.

The United States Intrauterine Device Market experienced strong demand growth because of increasing awareness regarding longterm contraception and declining unintended pregnancy rates. Nearly 14% of women using contraceptives in the United States selected intrauterine devices during 2025. Hormonal intrauterine devices accounted for 73% of prescriptions in urban hospitals, while copper devices represented 27%. More than 6 million women in the country actively used intrauterine devices, supported by over 19,000 gynecology clinics offering insertion procedures. Public healthcare initiatives contributed to 32% of total contraceptive counseling sessions involving intrauterine devices. Women between 25 and 34 years represented 46% of total users across the United States market.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: More than 68% of women preferred longacting reversible contraceptives due to effectiveness rates above 99%, while nearly 54% selected intrauterine devices because they required less than 1 annual clinical followup.

• Major Market Restraint: Approximately 31% of potential users reported concerns regarding discomfort during insertion, while 22% avoided intrauterine devices due to fear of hormonal side effects and misconceptions.

• Emerging Trends: Around 48% of manufacturers focused on hormonecontrolled release technologies, while 37% of healthcare providers adopted digital patient tracking systems for postinsertion monitoring during 2025.

• Regional Leadership: North America accounted for 34% of global intrauterine device demand, while Europe represented 29% because of public healthcare reimbursement programs and increased contraceptive awareness.

• Competitive Landscape: The top five manufacturers controlled nearly 67% of global device distribution, while hormonal intrauterine devices contributed approximately 61% of total installed units worldwide during 2025.

• Market Segmentation: Hormonal intrauterine devices represented 61% of product demand, while women aged 2534 accounted for 46% of total procedures performed globally during 2025.

• Recent Development: More than 42% of product launches between 2023 and 2025 focused on smaller frame devices, while 33% of manufacturers expanded clinical trials for extended usage periods.

Intrauterine Device Market Latest Trends

The Intrauterine Device Market is witnessing strong technological and clinical advancements driven by rising demand for effective longterm contraception. During 2025, hormonal intrauterine devices accounted for 61% of total procedures globally because of reduced menstrual bleeding and higher patient satisfaction rates. Copper intrauterine devices maintained significant adoption levels with 39% market penetration, especially in regions where hormonefree contraception remained a priority. More than 72 countries expanded public healthcare reimbursement coverage for intrauterine device insertion procedures during 2024 and 2025.

Healthcare providers increasingly adopted smaller and flexible device structures to improve patient comfort. Nearly 44% of newly launched devices featured slimmer insertion tubes, reducing discomfort during placement procedures. Digital healthcare integration also emerged as a major trend, with approximately 36% of gynecology clinics using mobile tracking applications for appointment scheduling and replacement reminders.

How is technological advancement driving the Intrauterine Device Market?

Technological advancement is driving the Intrauterine Device Market through the development of smaller, more flexible devices, improved hormone-release technologies, and digital healthcare integration. During 2025, around 48% of manufacturers focused on controlled hormone-release systems to improve contraceptive effectiveness and reduce side effects. Nearly 44% of newly launched devices featured slimmer insertion tubes that enhanced patient comfort during placement procedures. In addition, approximately 36% of gynecology clinics adopted digital tracking applications for appointment scheduling, follow-up monitoring, and replacement reminders. These innovations are improving patient experience, increasing physician confidence, and supporting higher adoption of long-acting reversible contraceptive methods.

Intrauterine Device Market Dynamics

The Intrauterine Device Market is influenced by rising contraceptive awareness, supportive healthcare programs, and technological innovations in longacting reversible contraception. More than 850 million women globally sought modern contraceptive services during 2025, while intrauterine devices represented one of the fastest adopted methods due to effectiveness rates exceeding 99%. Approximately 64% of gynecologists in developed countries recommended hormonal intrauterine devices because of reduced menstrual symptoms. Public healthcare systems in over 90 countries subsidized insertion procedures, improving accessibility among lowincome populations.

DRIVER

Rising demand for longacting reversible contraception.

The growing preference for long-acting reversible contraception is the primary factor driving the expansion of the intrauterine device market. Women are increasingly choosing contraceptive solutions that provide long-term protection, require minimal maintenance, and offer high effectiveness compared to short-term alternatives. Healthcare providers continue recommending intrauterine devices because they support family planning, reduce the risk of unintended pregnancies, and eliminate the need for daily compliance associated with oral contraceptives. Government health agencies, non-governmental organizations, and reproductive health programs are expanding awareness campaigns to encourage the adoption of safe and reliable contraceptive methods, particularly among women seeking convenient long-term reproductive healthcare options.

Improving access to gynecological services, wider insurance coverage, and supportive public healthcare policies continue strengthening market demand across developed and emerging economies. Advances in hormonal and copper-based device technologies have enhanced patient satisfaction by extending device lifespan, improving comfort, and reducing replacement frequency. Healthcare professionals are also emphasizing personalized contraceptive counseling to help women select the most appropriate long-term solution based on their medical needs and reproductive goals. More than 71% of women selecting reversible contraception preferred long-term contraceptive methods, highlighting the strong demand for intrauterine devices.

RESTRAINT

Concerns regarding side effects and insertion discomfort.

Concerns related to insertion discomfort, temporary side effects, and misconceptions regarding intrauterine devices continue to restrain broader market adoption. Many women remain hesitant because of anxiety surrounding the insertion procedure, while others delay treatment due to concerns about cramping, irregular bleeding, or perceived long-term health effects. Limited access to qualified healthcare professionals capable of providing counseling and safe insertion services further contributes to lower adoption rates in several regions. In addition, misinformation regarding fertility, reproductive health, and device safety continues influencing contraceptive decisions among potential users.

Healthcare providers continue investing in patient education, counseling programs, and improved clinical practices to address these concerns and enhance user confidence. Technological improvements in device design and insertion techniques are helping reduce procedural discomfort while improving patient experiences during and after implantation. Despite these advancements, educational gaps and misconceptions remain barriers to wider adoption in both developed and developing healthcare systems. Approximately 31% of potential users postponed adoption because of concerns regarding insertion discomfort.

OPPORTUNITY

Expansion of women’s healthcare programs and digital health integration.

The expansion of women's healthcare programs and increasing adoption of digital healthcare platforms present significant growth opportunities for the intrauterine device market. Governments and international health organizations continue increasing investment in reproductive healthcare services, family planning initiatives, and preventive women's health programs that improve access to long-term contraceptive options. Expanded healthcare funding has enabled broader availability of contraceptive counseling, device insertion procedures, and follow-up care through both public and private healthcare providers.

Digital health technologies are further transforming reproductive healthcare by enabling online consultations, appointment scheduling, remote patient education, and personalized contraceptive guidance. Telemedicine platforms and mobile health applications are improving communication between patients and healthcare professionals while increasing awareness of modern contraceptive solutions among younger populations. Approximately 38% of urban healthcare providers offered digital contraceptive consultations, demonstrating the growing role of technology in expanding access to reproductive healthcare services.

CHALLENGE

Limited awareness and uneven healthcare accessibility.

Unequal healthcare infrastructure and limited awareness continue to challenge the growth of the intrauterine device market, particularly across rural and underserved regions. Many communities continue experiencing shortages of trained gynecologists, reproductive health specialists, and primary healthcare professionals capable of providing comprehensive contraceptive counseling and safe device insertion. Geographic disparities in healthcare access often delay diagnosis, consultation, and treatment, reducing the availability of long-acting contraceptive options for women who could benefit from them.

Cultural beliefs, social stigma, and misinformation regarding fertility and contraceptive safety also influence healthcare decisions in several regions. Supply chain disruptions affecting medical device availability and uneven distribution of reproductive healthcare services further complicate market expansion. Governments and healthcare organizations continue strengthening awareness campaigns and healthcare workforce development; however, access disparities remain a major concern. Nearly 42% of women living in rural communities lacked access to specialized gynecological services, highlighting the ongoing challenge of equitable healthcare delivery.

Why is demand increasing for the Intrauterine Device Industry?

Demand for the Intrauterine Device Industry is increasing because more women are choosing long-acting, highly effective contraceptive methods supported by expanding family planning programs and greater reproductive health awareness. During 2025, more than 160 million women globally used modern contraceptives, with intrauterine devices accounting for nearly 18% of long-acting contraceptive adoption. Around 68% of women preferred long-acting reversible contraception because of effectiveness rates above 99% and minimal annual clinical follow-up requirements. Government healthcare programs in over 120 countries and increasing insurance coverage have also improved accessibility and encouraged wider adoption.

Segmentation Analysis

The intrauterine device market is segmented by type and application, reflecting varying contraceptive preferences, reproductive healthcare requirements, and patient demographics. Hormonal intrauterine devices continue dominating the market because they provide long-term pregnancy prevention while offering additional therapeutic benefits such as reduced menstrual bleeding and lower cramping. Copper intrauterine devices remain widely utilized by women seeking hormone-free contraception with extended product lifespan and proven clinical effectiveness. Hormonal intrauterine devices accounted for 61% of the overall market due to their growing acceptance among healthcare providers and patients.

Application trends are influenced by reproductive planning, lifestyle preferences, healthcare accessibility, and increasing awareness of long-acting reversible contraception among different age groups. Women in their late twenties and early thirties continue representing the largest patient population because many seek reliable contraceptive solutions that support career planning, delayed pregnancy, and long-term reproductive health management. Expanding family planning programs and digital healthcare initiatives continue encouraging adoption across younger age groups. Women aged 25–34 represented the largest application segment, reflecting strong demand for long-term contraceptive solutions.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

By Type

Hormonal IUD

Hormonal intrauterine devices remain the dominant product segment because they provide highly effective long-term contraception while also offering therapeutic benefits that improve menstrual health. These devices release controlled amounts of hormone to prevent pregnancy while reducing menstrual bleeding, minimizing cramping, and improving quality of life for many users. Healthcare professionals frequently recommend hormonal IUDs for women seeking both contraceptive protection and management of menstrual disorders. Hormonal IUDs represented 61% of the global market.

Continuous innovation in hormonal formulations, device design, and insertion techniques has enhanced patient comfort and extended product lifespan, reducing replacement frequency and improving treatment satisfaction. Growing physician confidence, increasing patient awareness, and expanding reimbursement coverage continue driving widespread adoption across hospitals, gynecology clinics, and reproductive healthcare centers worldwide.

Copper IUD

Copper intrauterine devices continue serving women who prefer hormone-free contraception while providing long-term pregnancy prevention with excellent clinical effectiveness. These devices remain popular because they offer extended contraceptive protection without hormonal exposure, making them suitable for women with specific medical preferences or contraindications to hormonal therapies. Copper IUDs accounted for 39% of total market demand.

Public healthcare systems and family planning programs continue promoting copper IUDs because of their affordability, long product lifespan, and suitability for large-scale reproductive healthcare initiatives. Ongoing improvements in device materials, insertion techniques, and patient counseling continue supporting stable adoption across both developed and emerging healthcare markets.

By Application

Age 2024

Women between the ages of 20 and 24 continue adopting intrauterine devices as awareness of reproductive health, family planning, and long-term contraception increases through educational institutions, digital healthcare platforms, and public health campaigns. Younger women are increasingly considering long-acting reversible contraception as they prioritize education, career development, and flexible reproductive planning. This age group accounted for 28% of the global market.

Growing access to university healthcare services, online reproductive health information, and specialized gynecological counseling continues improving confidence in modern contraceptive methods among first-time users. Healthcare providers are emphasizing individualized contraceptive counseling to ensure women understand the benefits, safety, and long-term effectiveness of intrauterine devices before making informed healthcare decisions.

Age 2534

Women aged 25 to 34 represent the largest application segment because this demographic increasingly seeks reliable long-term contraception that supports career planning, family planning flexibility, and reproductive health management. Higher workforce participation, delayed pregnancy planning, and greater healthcare awareness continue encouraging widespread adoption of intrauterine devices within this age group. Women aged 25–34 accounted for the largest share of global procedures.

Healthcare providers continue recommending intrauterine devices because they offer highly effective contraception with minimal maintenance requirements, allowing women to avoid daily medication while maintaining reproductive flexibility. Expanding insurance coverage, improved access to gynecological services, and greater acceptance of long-acting contraceptive methods continue supporting sustained market growth among women in this age category.

Which Segment is Growing Faster in the Intrauterine Device Market?

The hormonal intrauterine device segment is growing faster due to its long-lasting protection, reduced menstrual bleeding, and higher patient preference. Hormonal IUDs accounted for approximately 61% of total market demand during 2025, with more than 74 million women using these devices globally. Their replacement cycle of 5 to 8 years and ability to reduce menstrual symptoms have made them the preferred choice among healthcare providers. By application, women aged 25–34 represented the largest user group with 46% of total procedures, driven by delayed pregnancy planning and increasing workforce participation.

Intrauterine Device Market Regional Outlook

The global Intrauterine Device Market demonstrates strong regional variations influenced by healthcare accessibility, contraceptive awareness, and reimbursement policies. North America accounted for 34% of global demand during 2025 because of advanced gynecological infrastructure and high awareness regarding longacting reversible contraception. Europe represented 29% due to strong public healthcare support and widespread reimbursement programs. AsiaPacific contributed 27% driven by large population bases and increasing family planning initiatives. Middle East & Africa accounted for 10% because of improving healthcare investments and expanding women’s health campaigns.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America continues to lead the intrauterine device market due to its highly developed healthcare infrastructure, strong reproductive health awareness, and widespread availability of advanced gynecological services. Healthcare providers throughout the region actively promote long-acting reversible contraception as a safe, effective, and convenient family planning option, supported by favorable reimbursement policies and extensive insurance coverage. Hospitals, women's health clinics, and specialized reproductive healthcare centers continue expanding contraceptive counseling services while integrating personalized treatment approaches that improve patient satisfaction and long-term contraceptive adherence. North America accounted for 34% of the global intrauterine device market.

The region also benefits from continuous innovation in women's healthcare, increasing physician training, and strong regulatory support for modern contraceptive technologies. Growing adoption of digital health platforms, telemedicine consultations, and electronic patient management systems has improved access to reproductive healthcare services, particularly among younger populations. Public health initiatives, educational campaigns, and collaboration between healthcare providers and women's health organizations continue increasing awareness regarding long-acting contraception while supporting sustained market expansion across the United States and Canada.

Europe

Europe remains one of the most mature markets for intrauterine devices because of comprehensive public healthcare systems, strong reimbursement policies, and widespread awareness of reproductive health management. Governments across the region actively support family planning services through publicly funded healthcare programs, allowing women to access long-term contraceptive options with minimal financial barriers. Healthcare professionals continue recommending intrauterine devices as an effective contraceptive solution due to their long duration of action, high clinical effectiveness, and proven safety profile. Europe represented 29% of the global market.

Ongoing investment in women's healthcare services, preventive medicine, and reproductive health education continues strengthening market growth throughout the region. Gynecological associations actively promote evidence-based contraceptive counseling while healthcare providers integrate digital consultation platforms and personalized treatment planning into routine clinical practice. Increasing participation in preventive healthcare programs and continuous innovation in contraceptive technologies are expected to maintain strong regional demand over the coming years.

AsiaPacific

Asia-Pacific continues experiencing significant growth due to its large reproductive-age population, expanding healthcare infrastructure, and increasing government investment in family planning initiatives. Countries throughout the region are strengthening women's healthcare services through improved access to gynecological care, reproductive health education, and subsidized contraceptive programs that encourage wider adoption of long-acting reversible contraception. Asia-Pacific accounted for 27% of the global intrauterine device market.

Rapid urbanization, improving healthcare accessibility, and rising awareness regarding reproductive planning continue supporting increased demand across both developed and emerging economies. Governments, healthcare providers, and international organizations are expanding educational campaigns to improve contraceptive awareness while strengthening healthcare delivery systems in rural communities. Continued investment in women's health services, digital healthcare technologies, and reproductive medicine is expected to support sustained regional market expansion.

Middle East & Africa

The Middle East & Africa market is gradually expanding as governments increase investment in women's healthcare, maternal health programs, and reproductive health awareness initiatives. Healthcare systems across the region are strengthening access to gynecological services while expanding family planning programs that encourage informed contraceptive decision-making among women. Public healthcare providers, non-governmental organizations, and international health agencies continue collaborating to improve reproductive healthcare accessibility throughout both urban and rural communities. The region represented 10% of the global market.

Ongoing improvements in healthcare infrastructure, physician training, and public education campaigns are helping reduce misconceptions surrounding long-acting contraceptive methods while improving patient confidence in modern reproductive healthcare. Expansion of specialized women's health centers, increased availability of trained healthcare professionals, and stronger government support for preventive healthcare services are expected to further improve adoption of intrauterine devices across the Middle East and Africa.

Which Region Dominates the Intrauterine Device Industry?

North America dominates the Intrauterine Device Industry with approximately 34% of global demand, supported by advanced healthcare infrastructure, strong contraceptive awareness, and broad insurance coverage. More than 6 million women in the United States actively used intrauterine devices during 2025, while hormonal devices accounted for nearly 73% of total insertions. High physician recommendation rates, widespread availability of gynecology clinics, and supportive public reproductive health programs have strengthened the region's leadership. Continuous product innovation and increasing awareness of long-term contraception continue to support North America's dominant position in the global market.

List of Top Intrauterine Device Companies

• Bayer
• Merck
• Teva Pharmaceutical
• Allergan
• HRA Pharma
• Eurogine
• Yantai JiShengYaoXie
• TianYi
• SMB Corporation
• Shenyang Liren
• H & J Medical

List of Top tow Companies Market Share

• Bayer accounted for approximately 32% of global intrauterine device distribution during 2025 due to extensive hormonal device portfolios, strong physician networks, and operations across more than 100 countries.

• Merck represented approximately 18% of global market presence through advanced contraceptive research, broad healthcare partnerships, and increasing adoption of longacting reproductive health products.

Investment Analysis and Opportunities

Investments in the Intrauterine Device Market increased substantially due to rising demand for longacting contraceptive technologies and expanding women’s healthcare programs. More than 120 countries increased public healthcare funding for family planning initiatives during 2025. Approximately 43% of investments focused on hormonal intrauterine device innovation, particularly lowdose hormone technologies and flexible frame designs.

Manufacturers expanded production capacities across AsiaPacific and Europe to support increasing global demand. Nearly 29 new production facilities and assembly centers became operational between 2023 and 2025. Research institutions initiated over 110 clinical studies focused on reducing side effects, extending usage duration, and improving insertion comfort.

New Product Development

New product development within the Intrauterine Device Market focused heavily on patient comfort, extended protection periods, and improved hormonal delivery systems. Nearly 48% of ongoing research projects during 2025 involved lowdose hormone technologies designed to reduce irregular bleeding and hormonal side effects. Manufacturers also introduced slimmer insertion tubes, reducing discomfort during placement procedures by approximately 27%.

More than 33% of recently launched products featured flexible frames designed to improve uterine compatibility and reduce expulsion risks. Advanced biocompatible polymer coatings gained attention because they reduced inflammation and improved longterm retention rates. Clinical trials involving biodegradable materials increased by 19% during 2025.

Five Recent Developments (20232025)

• Bayer expanded hormonal intrauterine device distribution into 18 additional countries during 2024, increasing patient access across public healthcare systems and supporting more than 2 million additional procedures.

• Merck initiated advanced clinical trials during 2025 involving lowdose hormonal technologies designed to reduce irregular bleeding by approximately 21% among longterm users.

• Eurogine launched a smaller frame copper intrauterine device during 2024 targeting women aged 2024, improving insertion comfort scores by nearly 26% during clinical evaluations.
• SMB Corporation upgraded manufacturing facilities in AsiaPacific during 2025, increasing annual production capacity by approximately 31% to address growing regional demand.

• HRA Pharma expanded digital reproductive healthcare initiatives during 2023, supporting online contraceptive consultations for more than 1.4 million women across European healthcare networks.

Report Coverage of Intrauterine Device Market

The report coverage of the Intrauterine Device Market provides detailed analysis of product types, applications, regional trends, competitive positioning, and technological developments influencing industry expansion. The report evaluates hormonal intrauterine devices and copper intrauterine devices, covering effectiveness rates, patient preferences, and replacement duration ranging from 3 years to 10 years.

The study includes segmentation analysis across women aged 2024, 2534, and 3544, highlighting adoption patterns and contraceptive preferences within each demographic. Regional analysis covers North America, Europe, AsiaPacific, and Middle East & Africa, representing more than 120 countries involved in reproductive healthcare programs during 2025.The report also examines healthcare infrastructure, physician training availability, public awareness campaigns, and digital health integration trends.

Intrauterine Device Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 3377.58 Million in 2026
Market Size Value By	USD 4720.08 Million by 2035
Growth Rate	CAGR of 3.79% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Hormonal IUD Copper IUD By Application : Age 20-24 Age 25-34 Age 35-44
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample